Personalized Peptide Microarrays for Rapid Tumor Antigen Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies face limitations in identifying putative cancer antigens rapidly, which hinders their efficacy, as existing methods are technically challenging and do not effectively promote targeted anti-tumor responses or sufficient cooperation between immune cells.
Innovation Solution
The development of personalized peptide microarrays containing mutant and wild-type peptides, derived from high-frequency cancer genes, allows for rapid identification of tumor antigens through antibody binding analysis, enabling targeted immunotherapies and monitoring of treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional methods are used to identify cancer antigens, then the identification process is thorough, but the process is technically challenging and time-consuming
Solution Approach 1:
The patent pre-constructs peptide libraries containing mutant and wild-type peptides from high-frequency cancer genes before patient-specific antigen identification. This preliminary preparation of comprehensive peptide arrays enables rapid screening without time-consuming custom synthesis for each patient, resolving the contradiction between thorough identification and time efficiency
Solution Approach 2:
The invention creates a universal peptide library that can screen multiple potential cancer antigens simultaneously using a single platform. The peptide array contains diverse mutant peptides from various cancer genes that can be used across different patients, eliminating the need for separate identification processes for each patient while maintaining comprehensive coverage
2Quantity of substance
If comprehensive cancer gene sequencing is performed, then all mutations are identified, but the complexity of analyzing and selecting relevant antigens increases
Solution Approach 1:
The patent focuses screening efforts on high-frequency cancer genes and their corresponding mutant peptides rather than analyzing all possible mutations. By concentrating resources on the most relevant peptide subsets based on mutation frequency and immunogenicity potential, the system reduces analysis complexity while maintaining identification comprehensiveness
Solution Approach 2:
The invention introduces peptide arrays as an intermediary platform between genome sequencing and antigen identification. This intermediate step translates complex genomic mutation data into a standardized format that can be efficiently screened using antibody binding assays, simplifying the selection process by providing a uniform interface for analyzing diverse mutations
3Measurement precision
If personalized peptide arrays are created for each patient, then patient-specific antigens are accurately identified, but the manufacturing process becomes more complex
Solution Approach 1:
The patent pre-constructs comprehensive peptide libraries containing mutant and wild-type peptides from high-frequency cancer genes before patient-specific antigen identification. This preliminary preparation of standardized peptide arrays enables rapid customization for each patient without time-consuming custom synthesis, resolving the contradiction between personalized accuracy and manufacturing simplicity
Solution Approach 2:
The invention divides the peptide library into modular segments organized by cancer gene and mutation type. This segmentation allows the array to be constructed from standardized modules that can be efficiently assembled and reproduced, reducing manufacturing complexity while maintaining the ability to provide comprehensive patient-specific screening
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the identification of patient-specific tumor antigens, enhancing the efficacy of cancer immunotherapies by targeting specific immune responses and monitoring treatment outcomes, potentially increasing complete remission rates beyond current limitations.
Implementation Method 1
contacting the peptide array with a biological sample from the subject for a time and under conditions to permit binding of antibodies in the serum to the mutant peptides
Data Source
AI summary
Disclosed herein are isolated compositions including at least 2 of mutant peptides selected from the group consisting of SEQ ID NOS: 1-149, or polypeptides comprising the mutant peptides; wherein the composition comprises mutant peptides encoded by 2 or more genes. Also disclosed are methods for personalized treatment of breast cancer involving creating a peptide array of mutant peptides comprising the mutations in protein-encoding regions of the high-frequency cancer genes or the exome in a subject and screening the peptide array with a biological sample from the subject to detect antibodies in the biological sample that bind to the array, to detect antigenic targets for therapy in treating the subject.